Daxor Corp
Daxor Corp is a closed-end fund that provides investment products and services to institutional and individual investors, primarily through its collective investment vehicles.
Business. Daxor Corp is a closed-end fund that provides investment products and services to institutional and individual investors, primarily through its collective investment vehicles.
Analyst recommendations
2 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Daxor Corp is a closed-end fund that provides investment products and services to institutional and individual investors, primarily through its collective investment vehicles.
Daxor Corp maintains a strong capital structure with a debt-to-equity ratio of 0.0, indicating no long-term debt obligations. The company's liquidity position is characterized by a low risk profile, with total liabilities amounting to $122,600 and total equity of $45,887,270. The price-to-book ratio of 1.33 and price-to-tangible-book ratio of 1.33 suggest that the company is trading at a slight premium to its book value.
In terms of profitability, Daxor Corp's return on equity (ROE) of 19.98% and return on assets (ROA) of 19.93% are significantly higher than the typical benchmarks for closed-end funds, indicating strong returns relative to its equity and asset base. However, the company reported a net income of $9,169,770 despite a negative gross profit of -$1,045,510 and operating income of -$1,122,950, suggesting that non-operational gains or other income sources are contributing to its profitability.
Daxor Corp's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no geographic diversification provided in the available data. This lack of segment and geographic diversification may expose the company to higher concentration risk, particularly if its primary revenue source experiences volatility.
The company's growth trajectory is not clearly defined in the available data, as there are no specific revenue growth projections or historical growth rates provided. Analysts have assigned a mean price target of $22.50, with a median of $22.50 and a high of $23.00, indicating a consensus for a significant increase in the stock price. However, the mean recommendation of 2.00 (on a scale from 1 to 5) suggests a "Buy" rating, with no strong buy recommendations reported.
Daxor Corp's risk assessment indicates a low probability of dilution and no immediate filing-based liquidity or dilution flags. The company's capital structure is not expected to be significantly impacted by dilution in the near term, and there are no recent events or filings that suggest a need for additional capital raising.
Recent events and filings do not indicate any material changes in the company's operations or financial position. The company's operating cash flow of $570,940 suggests that it is generating positive cash from operations, which supports its liquidity position.
- Daxor Corp has a strong capital structure with no long-term debt and a low debt-to-equity ratio.
- The company's ROE and ROA are significantly higher than typical benchmarks for closed-end funds.
- Daxor Corp's revenue is concentrated in a single business segment, which may increase its exposure to concentration risk.
- Analysts have assigned a "Buy" rating to the stock, with a mean price target of $22.50.
- The company's liquidity position is strong, with no immediate dilution or liquidity flags detected.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | -0,21 |
| Revenue | —no estimate | —no estimate | 11,9M USD |
| Operating income | —no estimate | —no estimate | -1,2M USD |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Derivative transactions
- Director · Stock Options (right to buy) → COMMON STOCKAcquired 2 500 @ $10,14grant · 2026-06-23
- Director · Stock options (right to buy) → Common StockAcquired 2 500 @ $10,14grant · 2026-06-23
- Director · Stock Options (right to buy) → COMMON STOCKAcquired 2 500 @ $10,14grant · 2026-06-23
- Director · Stock Options (right to buy) → COMMON STOCKAcquired 2 500 @ $10,14grant · 2026-06-23
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Return On Equitynet_income / total_equity
- Price To Earningsmarket_price / (net_income / shares_outstanding_diluted)
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Daxor Corp Market data — financials · 2026-05-27
- Daxor Corp Market data — analyst estimates · 2026-05-27
Ownership & reference
Top holders
- Investment Managers · as of 2025-12-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$0M
- Brokerage Firms · as of 2026-03-310,00 %$0M
Insider activity
- Chief Financial Officer · Daxor Common StockOther 12 000 · 2026-06-23
- Director, Chief Executive Officer · Daxor Common StockOther 30 000 · 2026-06-23
- Director, Chief Scientific Officer · Daxor Common StockOther 25 000 · 2026-06-23
- Director, Chief Executive Officer · Daxor Common StockBought 1 000 @ $9,07$9K · 2026-04-08
- Chief Financial Officer · Daxor Common StockBought 1 000 @ $9,90$10K · 2026-03-31
- Chief Medical Officer · Daxor Common StockBought 2 285 · 2026-03-20
- Chief Medical Officer · Daxor Common StockBought 3 656 · 2026-03-20
- Director, Chief Scientific Officer · Daxor Common StockBought 18 000 · 2025-12-09
- Chief Financial Officer · Daxor Common StockBought 3 000 · 2025-12-09
- Chief Medical Officer · Daxor Common StockBought 2 344 · 2025-11-12